Siegfried Holding AG stock analysis
Siegfried Holding AG (0QQO) Share Price & Analysis
0QQO Stock Chart & Stats
- Day’s Range
- CHF 69.50 - CHF 70.48
- 52-Week Range
- CHF 65.20 - CHF 101.20
- Previous Close
- CHF 70.00
- Volume
- N/A
- Average Volume (3M)
- 8,981
- Market Cap
- CHF 3.17B
- Enterprise Value
- CHF 3.93B
- Total Cash (Recent Filing)
- CHF 105.16M
- Total Debt (Recent Filing)
- CHF 925.20M
- Price to Earnings (P/E)
- 18.0
- Beta
- 0.47
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- 2.51
- Last Dividend Ex-Date
- Apr 28, 2026
- Dividend Yield
- 0.57%
Bulls Say, Bears Say
Bulls Say
Profitable Growth
Siegfried has expanded revenue substantially while maintaining healthy profitability, with 2025 operating and EBITDA margins of 15.8% and 23.1%. This combination supports reinvestment, strengthens resilience across the CDMO cycle, and indicates meaningful earnings power beyond short-term demand fluctuations.
Expanded Global CDMO Footprint
The acquired U.S. and Australian sites broaden Siegfried’s geographic reach, capacity base, and customer access in drug substances. Integration is on track, while an expected annualized contribution of about USD 100m and additional U.S. capacity support a larger platform for recurring commercial manufacturing.
Stronger Commercial Pipeline
Rising request-for-proposal activity provides evidence of improving commercial traction across both business areas. Combined with strong project inflow and twice as many new innovation customers in drug substances, this expands the potential order pipeline and can support future utilization and recurring supply revenue.
Bears Say
Weak Cash Conversion
Persistently weak free-cash-flow conversion limits the cash available for debt reduction, investment, and shareholder returns despite reported earnings. The pattern suggests that capital spending or working-capital needs can absorb operating profits, leaving less financial flexibility if execution or demand weakens.
Higher Post-acquisition Leverage
The acquisition increases financial obligations and makes deleveraging an important execution priority over the next several quarters. Higher leverage can constrain capital allocation and amplify the effect of weaker cash generation, while expanded bond financing also raises exposure to ongoing financial expenses.
Working-capital Drag
The substantial inventory build ties up cash and has already contributed to lower operating cash flow following the acquisition. Although partly linked to consolidation and seasonal production, sustained working-capital absorption could delay deleveraging and reduce the near-term benefits of improved operating profitability.
Siegfried Holding AG News
0QQO FAQ
What was Siegfried Holding AG’s price range in the past 12 months?
What is Siegfried Holding AG’s market cap?
When is Siegfried Holding AG’s upcoming earnings report date?
How were Siegfried Holding AG’s earnings last quarter?
Is Siegfried Holding AG overvalued?
Does Siegfried Holding AG pay dividends?
What is Siegfried Holding AG’s EPS estimate?
How many shares outstanding does Siegfried Holding AG have?
What happened to Siegfried Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Siegfried Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Siegfried Holding AG
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Marcel Imwinkelried
- Employees
- 4,454
- Website
- www.siegfried.ch
- Address
- Untere Bruehlstrasse 4, Zofingen, AG, 4800, CH
Siegfried Holding AG (0QQO) Earnings & Revenues
0QQO Company Deck
0QQO Earnings Call
Earnings Call SentimentPositive
The call balanced clear operational and strategic progress (top-line growth, margin expansion, strong commercial traction, successful technology and site milestones, acquisition integration on track) against near-term financial impacts from the acquisition (lower operating cash flow, higher inventory and leverage, and FX headwinds). Management reconfirmed guidance and emphasized focus on cash generation and deleveraging, with multiple execution milestones supporting the strategic outlook.
View all GB:0QQO earnings summaries0QQO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |









